A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme alpha-galactosidase on gastrointestinal symptoms in irritable bowel syndrome patients
Bohn L, Tornblom H, Van Oudenhove L, Simren M, Storsrud S
Published in Neurogastroenterology and Motility
Key Findings
1200 GalU/meal alpha-galactosidase did not significantly reduce overall gastrointestinal symptoms or measured intestinal gas versus placebo after carbohydrate-rich meals in IBS patients.
Conclusions
Acute alpha-galactosidase gave no clear symptom benefit in IBS, contrasting with healthy-volunteer gas data.
Limitations
Pilot size, acute single-meal design, IBS-only population.
Supplements Studied
The aim of the study was to assess if oral alpha-galactosidase is superior to placebo in reducing gastrointestinal (GI) symptoms and intestinal gas production.
Outcomes Measured
The aim of the study was to assess if oral alpha-galactosidase is superior to placebo in reducing gastrointestinal (GI) symptoms and intestinal gas production after ingestion of carbohydrate-rich meals in adult patients with IBS.
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.